Drug competition issues.
Monitor drug supply chain issues.
Monitor budget issues relating to drug provisions of the Build Back Better Act.
Drug competition issues.
Monitor sovereign immunity issues relating to patent ownership.
Monitor S.142 - Preserve Access to Affordable Generics and Biosimilars Act as it related to patent settlement issues.
Monitor issues relating to the treatment of pharmaceutical patents in inter partes reviews.
Monitor S.150 - Affordable Prescriptions for Patients Act of 2023 as it related to product hopping.
Monitor issues relating to the structure of the Patent Trial and Appeal Board.
Monitor court decisions on skinny labeling issue.
Issues relating to the Patent Eligibility Restoration Act - S.2140.
Issues relating to the PREVAIL Act - S.2220/H.R.4370.
Monitor issues relating to trade agreements.
Duration: September 1, 2016
to
present
General Issues: Health Issues , Labor Issues/Antitrust/Workplace , Copyright/Patent/Trademark , Trade (Domestic & Foreign) , Taxation/Internal Revenue Code , Pharmacy
Spending: about $910,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2016: House of Representatives, U.S. Senate, White House Office
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Joseph Gibson
Chief Minority Counsel, House Judiciary Committee 2007-2008; Chief of Staff, Rep. Lamar Smith 2005-2007; Chief Legislative Counsel & Parliamentarian, House Judiciary Committee 2003-2005; Deputy Asst. Attorney General, Office of Leg. Affairs 2002-2003
Counsel for Legislative & Intergovernmental Affairs Anti-Trust Division, DOJ 2001-2002; Chief Antitrust Counsel, House Judiciary Committee 1997-2001; Counsel, House Judiciary Committee 1995-1997
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on April 22.
Original Filing: 301570434.xml
Lobbying Issues
Drug competition issues.
Monitor drug supply chain issues.
Monitor budget issues relating to drug provisions of the Build Back Better Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Monitor sovereign immunity issues relating to patent ownership.
Monitor S.142 - Preserve Access to Affordable Generics and Biosimilars Act as it related to patent settlement issues.
Monitor issues relating to the treatment of pharmaceutical patents in inter partes reviews.
Monitor S.150 - Affordable Prescriptions for Patients Act of 2023 as it related to product hopping.
Monitor issues relating to the structure of the Patent Trial and Appeal Board.
Monitor court decisions on skinny labeling issue.
Issues relating to the Patent Eligibility Restoration Act - S.2140.
Issues relating to the PREVAIL Act - S.2220/H.R.4370.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues relating to trade agreements.
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2023
In Q4, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on Jan. 22.
Original Filing: 301536648.xml
Lobbying Issues
Drug competition issues.
Monitor drug supply chain issues.
Monitor budget issues relating to drug provisions of the Build Back Better Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Monitor sovereign immunity issues relating to patent ownership.
Monitor S.142 - Preserve Access to Affordable Generics and Biosimilars Act as it related to patent settlement issues.
Monitor issues relating to the treatment of pharmaceutical patents in inter partes reviews.
Monitor S.150 - Affordable Prescriptions for Patients Act of 2023 as it related to product hopping.
Monitor issues relating to the structure of the Patent Trial and Appeal Board.
Monitor court decisions on skinny labeling issue.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues relating to trade agreements.
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2023
In Q3, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on Oct. 20, 2023.
Original Filing: 301509944.xml
Lobbying Issues
Drug competition issues.
Monitor drug supply chain issues.
Monitor budget issues relating to drug provisions of the Build Back Better Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Monitor sovereign immunity issues relating to patent ownership.
Monitor S.142 - Preserve Access to Affordable Generics and Biosimilars Act as it related to patent settlement issues.
Monitor issues relating to the treatment of pharmaceutical patents in inter partes reviews.
Monitor S.150 - Affordable Prescriptions for Patients Act of 2023 as it related to product hopping.
Monitor issues relating to the structure of the Patent Trial and Appeal Board.
Court decisions on skinny labeling issue.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues relating to trade agreements.
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2023
In Q2, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on July 20, 2023.
Original Filing: 301487644.xml
Lobbying Issues
Drug competition issues.
Monitor drug supply chain issues.
Monitor budget issues relating to drug provisions of the Build Back Better Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Monitor sovereign immunity issues relating to patent ownership.
S.142 - Preserve Access to Affordable Generics and Biosimilars Act as it related to patent settlement issues.
Monitor issues relating to the treatment of pharmaceutical patents in inter partes reviews.
S.150 - Affordable Prescriptions for Patients Act of 2023 as it related to product hopping.
Issues relating to the structure of the Patent Trial and Appeal Board.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues relating to trade agreements.
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2023
In Q1, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on April 20, 2023.
Original Filing: 301460329.xml
Lobbying Issues
Drug competition issues.
Monitor drug supply chain issues.
Monitor budget issues relating to drug provisions of the Build Back Better Act.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Monitor sovereign immunity issues relating to patent ownership.
Monitor Patent Settlement issues.
Monitor issues relating to the treatment of pharmaceutical patents in inter partes reviews.
Monitor product hopping.
Issues relating to the structure of the Patent Trial and Appeal Board.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues relating to trade agreements.
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2022
In Q4, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on Jan. 20, 2023.
Original Filing: 301436739.xml
Lobbying Issues
Drug competition issues.
Monitor drug supply chain issues.
Monitor budget issues relating to drug provisions of the Build Back Better Act.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Monitor sovereign immunity issues relating to patent ownership.
Monitor H.R.2981: Patent Settlement issues.
Monitor issues relating to the treatment of pharmaceutical patents in inter partes reviews.
Monitor H.R.2873: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 - product hopping.
Issues relating to the structure of the Patent Trial and Appeal Board.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues relating to trade agreements.
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2022
In Q3, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on Oct. 20, 2022.
Original Filing: 301412969.xml
Lobbying Issues
Drug competition issues.
Monitor drug supply chain issues.
Monitor budget issues relating to drug provisions of the Build Back Better Act.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Monitor sovereign immunity issues relating to patent ownership.
Monitor H.R.2981: Patent Settlement issues.
Monitor issues relating to the treatment of pharmaceutical patents in inter partes reviews.
Monitor H.R.2873: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 - product hopping.
Issues relating to the structure of the Patent Trial and Appeal Board.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues relating to trade agreements.
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2022
In Q2, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on July 20, 2022.
Original Filing: 301390010.xml
Lobbying Issues
Drug competition issues.
Monitor drug supply chain issues.
Monitor budget issues relating to drug provisions of the Build Back Better Act.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Monitor sovereign immunity issues relating to patent ownership.
Monitor H.R.2981: Patent Settlement issues.
Monitor issues relating to the treatment of pharmaceutical patents in inter partes reviews.
Monitor H.R.2873: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 - product hopping.
Issues relating to the structure of the Patent Trial and Appeal Board.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues relating to trade agreements.
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2022
In Q1, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on April 20, 2022.
Original Filing: 301365070.xml
Lobbying Issues
Drug competition issues.
Monitor drug supply chain issues.
Monitor budget issues relating to drug provisions of the Build Back Better Act.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Monitor sovereign immunity issues relating to patent ownership.
Monitor H.R.2891: Preserve Access to Affordable Generics and Biosimilars Act.
Monitor issues relating to the treatment of pharmaceutical patents in inter partes reviews.
Monitor H.R.2873: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 - product hopping.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues relating to trade agreements.
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2021
In Q4, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on Jan. 20, 2022.
Original Filing: 301331459.xml
Lobbying Issues
Drug competition issues.
Monitor drug supply chain issues.
Budget issues relating to drug provisions of the Build Back Better Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Monitor sovereign immunity issues relating to patent ownership.
Monitor H.R.2891: Preserve Access to Affordable Generics and Biosimilars Act.
Monitor issues relating to the treatment of pharmaceutical patents in inter partes reviews.
Monitor H.R.2873: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 - product hopping.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues relating to trade agreements.
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2021
In Q3, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on Oct. 20, 2021.
Original Filing: 301309057.xml
Lobbying Issues
Drug competition issues.
Monitor drug supply chain issues.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Monitor sovereign immunity issues relating to patent ownership.
H.R.2891: Preserve Access to Affordable Generics and Biosimilars Act.
Monitor issues relating to the treatment of pharmaceutical patents in inter partes reviews.
H.R.2873: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021.
H.R.2884: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues relating to trade agreements.
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2021
In Q2, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on July 20, 2021.
Original Filing: 301284119.xml
Lobbying Issues
Drug competition issues.
Drug supply chain issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Monitor sovereign immunity issues relating to patent ownership.
Patent settlement issues.
Issues relating to the treatment of pharmaceutical patents in inter partes reviews.
Monitor issues relating to product hopping.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues relating to trade agreements.
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2021
In Q1, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on April 20, 2021.
Original Filing: 301261310.xml
Lobbying Issues
Drug competition issues.
Drug supply chain issues.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Monitor sovereign immunity issues relating to patent ownership.
Monitor patent settlement issues.
Monitor issues relating to the treatment of pharmaceutical patents in inter partes reviews.
Monitor issues relating to product hopping.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues relating to trade agreements.
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2020
In Q4, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on Jan. 20, 2021.
Original Filing: 301238137.xml
Lobbying Issues
Drug competition issues.
Drug supply chain issues.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Monitor sovereign immunity issues relating to patent ownership.
Monitor patent settlement issues.
H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019.
S.64: Preserve Access to Affordable Generics and Biosimilars Act.
Monitor issues relating to the treatment of pharmaceutical patents in inter partes reviews.
Monitor issues relating to product hopping.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues relating to trade agreements.
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2020
In Q3, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on Oct. 20, 2020.
Original Filing: 301217659.xml
Lobbying Issues
Drug competition issues.
Drug supply chain issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Monitor sovereign immunity issues relating to patent ownership.
Monitor patent settlement issues.
H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019.
S.64: Preserve Access to Affordable Generics and Biosimilars Act.
Monitor issues relating to the treatment of pharmaceutical patents in inter partes reviews.
Monitor issues relating to product hopping.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor issues relating to trade agreements.
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2020
In Q2, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on July 20, 2020.
Original Filing: 301194889.xml
Lobbying Issues
Drug competition issues.
Issues relating to abuse of citizens' petitions.
Drug supply chain issues.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Sovereign immunity issues relating to patent ownership.
Patent settlement issues.
H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019.
S.64: Preserve Access to Affordable Generics and Biosimilars Act.
Issues relating to the treatment of pharmaceutical patents in inter partes reviews.
Issues relating to product hopping.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to trade agreements.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2020
In Q1, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on April 20, 2020.
Original Filing: 301174810.xml
Lobbying Issues
Drug competition issues.
Issues relating to abuse of citizens' petitions.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Sovereign immunity issues relating to patent ownership.
Patent settlement issues.
H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019.
S.64: Preserve Access to Affordable Generics and Biosimilars Act.
Issues relating to the treatment of pharmaceutical patents in inter partes reviews.
Issues relating to product hopping.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to trade agreements.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2019
In Q4, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on Jan. 21, 2020.
Original Filing: 301125864.xml
Lobbying Issues
Drug competition issues.
H.R.965/S.340: CREATES Act.
Issues relating to abuse of citizens' petitions.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Drug competition issues.
H.R.965/S.340: CREATES Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Sovereign immunity issues relating to patent ownership.
Patent settlement issues.
H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019.
S.64: Preserve Access to Affordable Generics and Biosimilars Act.
Issues relating to the treatment of pharmaceutical patents in inter partes reviews.
Issues relating to product hopping.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to trade agreements.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2019
In Q3, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on Oct. 21, 2019.
Original Filing: 301073773.xml
Lobbying Issues
Drug competition issues.
H.R.965/S.340: CREATES Act.
Issues relating to abuse of citizens' petitions.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Drug competition issues.
H.R.965/S.340: CREATES Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Sovereign immunity issues relating to patent ownership.
Patent settlement issues.
H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019.
S.64: Preserve Access to Affordable Generics and Biosimilars Act.
Issues relating to the treatment of pharmaceutical patents in inter partes reviews.
Issues relating to product hopping.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to trade agreements.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2019
In Q2, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on July 22, 2019.
Original Filing: 301055146.xml
Lobbying Issues
Drug competition issues.
H.R.965/S.340: CREATES Act.
Issues relating to abuse of citizens' petitions.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Drug competition issues.
H.R.965/S.340: CREATES Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Sovereign immunity issues relating to patent ownership.
Patent settlement issues.
H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019.
S.64: Preserve Access to Affordable Generics and Biosimilars Act.
Issues relating to the treatment of pharmaceutical patents in inter partes reviews.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to trade agreements.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2019
In Q1, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on April 22, 2019.
Original Filing: 301034290.xml
Lobbying Issues
Drug competition issues.
H.R.965/S.340: CREATES Act.
Issues relating to abuse of citizens' petitions.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Drug competition issues.
H.R.965/S.340: CREATES Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Sovereign immunity issues relating to patent ownership.
Patent settlement issues.
H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019.
S.64: Preserve Access to Affordable Generics and Biosimilars Act.
Issues relating to the treatment of pharmaceutical patents in inter partes reviews.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2018
In Q4, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on Jan. 22, 2019.
Original Filing: 301013258.xml
Lobbying Issues
Drug competition issues.
H.R.2212/S.974: CREATES Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Health Issues Labor Issues/Antitrust/Workplace
Lobbying Issues
Sovereign immunity issues relating to patent ownership.
Patent settlement issues.
Issues relating to the treatment of pharmaceutical patents in inter pares reviews.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2018
In Q3, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on Oct. 22, 2018.
Original Filing: 300994600.xml
Lobbying Issues
Drug competition issues.
H.R.2212/S.974: CREATES Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Health Issues Labor Issues/Antitrust/Workplace
Lobbying Issues
Sovereign immunity issues relating to patent ownership.
Patent settlement issues.
Issues relating to the treatment of pharmaceutical patents in inter pares reviews.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2018
In Q2, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on July 20, 2018.
Original Filing: 300973099.xml
Lobbying Issues
Drug competition issues.
H.R.2212: CREATES Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Health Issues Labor Issues/Antitrust/Workplace
Lobbying Issues
Sovereign immunity issues relating to patent ownership.
Patent settlement issues.
Issues relating to the treatment of pharmaceutical patents in inter pares reviews.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2018
In Q1, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on April 20, 2018.
Original Filing: 300953301.xml
Lobbying Issues
Drug competition issues.
H.R.2212: CREATES Act of 2017.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Health Issues Labor Issues/Antitrust/Workplace
Lobbying Issues
Sovereign immunity issues relating to patent ownership.
Patent settlement issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2017
In Q4, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on Jan. 22, 2018.
Original Filing: 300932920.xml
Lobbying Issues
Drug competition issues.
H.R.2212: CREATES Act of 2017.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues Labor Issues/Antitrust/Workplace
Lobbying Issues
Sovereign immunity issues relating to patent ownership.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues relating to corporate tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
In Q3, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on Oct. 20, 2017.
Original Filing: 300911936.xml
Lobbying Issues
Drug competition issues.
H.R.2212: CREATES Act of 2017.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues Labor Issues/Antitrust/Workplace
Lobbying Issues
Sovereign immunity issues relating to patent ownership.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
General corporate tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2017
In Q2, The Gibson Group, LLC lobbied for Association for Accessible Medicines , earning $30,000. The report was filed on July 20, 2017.
Original Filing: 300893267.xml
Lobbying Issues
Drug competition issues.
H.R.2212: CREATES Act of 2017.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues Labor Issues/Antitrust/Workplace
1st Quarter, 2017
In Q1, The Gibson Group, LLC lobbied for Association for Accessible Medicines (FKA Generic Pharmaceutical Association) , earning $30,000. The report was filed on April 20, 2017.
Original Filing: 300871902.xml
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues Labor Issues/Antitrust/Workplace
4th Quarter, 2016
In Q4, The Gibson Group, LLC lobbied for Generic Pharmaceutical Association , earning $30,000. The report was filed on Jan. 23, 2017.
Original Filing: 300854786.xml
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues Labor Issues/Antitrust/Workplace
3rd Quarter, 2016
In Q3, The Gibson Group, LLC lobbied for Generic Pharmaceutical Association , earning $10,000. The report was filed on Oct. 20, 2016.
Original Filing: 300834697.xml
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues Labor Issues/Antitrust/Workplace
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate